Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Alirocumab (Praluent) vs Icosapent Ethyl (Vascepa): they're closely matched on evidence (4.5 vs 4.2/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Alirocumab (Praluent) and Icosapent Ethyl (Vascepa) are closely matched across evidence, studies, and safety.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (2)
Outcomes where both Alirocumab (Praluent) and Icosapent Ethyl (Vascepa) have evidence — compare verdict strength side-by-side.
Prescription dosing is 75 mg or 150 mg subcutaneously every 2 weeks (a 300 mg every-4-weeks option exists), titrated by a clinician to the LDL-C target. A prescription drug; not a self-administered supplement regimen.
any
Subcutaneous prefilled pen/syringe (alirocumab)
Approved dose is 2 g twice daily (4 g/day total) taken with food, under a clinician, for statin-treated adults with elevated triglycerides and high cardiovascular risk. A prescription drug — not a self-directed regimen.
with-meals
Oral capsule — purified EPA ethyl ester (icosapent ethyl)
Within weeks
Months to years
Years
At each injection
Months to years
Weeks
Weeks to months
Throughout use
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
The New England journal of medicine (2018) · Rct · n=18924
ODYSSEY OUTCOMES randomized trial of ~18,900 patients 1–12 months after acute coronary syndrome on intensive statins
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
The New England journal of medicine (2015) · Rct · n=2341
ODYSSEY LONG TERM randomized trial in high-cardiovascular-risk patients on maximally tolerated statins
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia.
European heart journal (2015) · Rct · n=735
Pooled ODYSSEY FH I and FH II randomized trials in 735 heterozygous familial-hypercholesterolemia patients
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
The New England journal of medicine (2019) · Rct · n=8179
REDUCE-IT: 8,179 statin-treated patients with elevated triglycerides and high cardiovascular risk
Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.
Journal of the American College of Cardiology (2019) · Rct · n=8179
REDUCE-IT secondary analysis of total (first plus recurrent) ischemic events
Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the MARINE trial).
The American journal of cardiology (2011) · Rct
MARINE: randomized, placebo-controlled trial in patients with very high triglycerides (≥500 mg/dL)
Both Alirocumab (Praluent) and Icosapent Ethyl (Vascepa) are closely matched — the best choice depends on your specific health goals.
For support heart health, Alirocumab (Praluent) has a higher relevance score (80 vs 72).
No known interactions between Alirocumab (Praluent) and Icosapent Ethyl (Vascepa) have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.